Novo Nordisk Q3 results: Ozempic maker’s profit falls 27%; cuts 9,000 jobs
[ad_1] Danish pharmaceutical giant Novo Nordisk, the maker of obesity drugs Ozempic and Wegovy, lowered its 2025 sales outlook for the fourth time this year on Wednesday after reporting tepid third-quarter results.The company, which appointed Mike Doustdar as CEO in August, now expects full-year sales growth of 8 to 11 per cent, down from a…